Australia markets closed

Allogene Therapeutics, Inc. (ALLO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
18.91+0.16 (+0.85%)
At close: 04:00PM EST
18.91 0.00 (0.00%)
After hours: 05:39PM EST
Full screen
Trade prices are not sourced from all markets
Previous close18.75
Open18.55
Bid0.00 x 1400
Ask0.00 x 1000
Day's range17.86 - 19.11
52-week range12.90 - 39.12
Volume655,968
Avg. volume1,942,277
Market cap2.695B
Beta (5Y monthly)0.76
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    Allogene Therapeutics Announces Conference Call to Review ALPHA, ALPHA2 and UNIVERSAL Phase 1 Data Presented at the 2021 American Society of Hematology Annual Meeting

    Conference Call and Webcast Scheduled for Monday, December 13, 2021 at 1:30 PM PT/4:30 PM ET SOUTH SAN FRANCISCO, Calif., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR Tβ„’) therapies for cancer, today announced that management will host a conference call to review data to be presented at the American Society of Hematology Annual Meeting from the ALPHA and ALPHA2 Phase 1 t

  • GlobeNewswire

    Allogene Therapeutics Announces Participation in Five Upcoming Virtual Investor Conferences

    SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR Tβ„’) therapies for cancer, today announced that management plans to participate in five upcoming virtual investor conferences. Cowen's 5th Annual IO Next SummitMonday, November 15, 20218:45 AM PT/11:45 AM ET Stifel 2021 Virtual Healthcare ConferenceTuesday, November 16, 202111:00 AM PT/2:00 PM ET J

  • GlobeNewswire

    Allogene Therapeutics Reports Third Quarter 2021 Financial Results and Business Update

    New Clinical Data from the ALPHA, ALPHA2 and UNIVERSAL AlloCAR Tβ„’ Trials to be Presented at the 63rd Annual Meeting of the American Society of Hematology ALPHA2 Study Abstract Selected for Oral Presentation Highlights the Benefits of Consolidation Dosing with ALLO-501A in Patients with Relapsed/Refractory Large B Cell LymphomaALPHA Study Abstract Selected for Poster Presentation Continues to Show Durability of Responses to ALLO-501 in Patients with Non-Hodgkin LymphomaUNIVERSAL Study Abstract Se